Century Therapeutics (IPSC) risk factors
Item 1A of every Century Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors86 risks10 new11 dropped25 reworded
Century Therapeutics experienced a workforce reduction, dropping full-time headcount from 150 to 78 employees. The company shifted its pipeline focus toward lead candidate CNTY-813 and CNTY-308. Net losses narrowed significantly to $9.6 million in 2025.
Filed Mar 12, 2026 - FY2024 10-K risk factors87 risks
Century Therapeutics faces significant recurring losses and is dependent on advancing its lead allogeneic cell therapy candidate, CNTY-101. The company relies heavily on specialized manufacturing platforms and strategic partnerships like Bayer and FCDI. Nasdaq listing compliance regarding minimum bid price is an immediate operational concern.
Filed Mar 19, 2025